TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 170 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $921,600 | -95.9% | 60,000 | -94.0% | 0.18% | -95.9% |
| Q1 2023 | $22,557,470 | +125.8% | 1,003,000 | +111.2% | 4.43% | +126.2% |
| Q4 2022 | $9,989,250 | -58.0% | 475,000 | -50.8% | 1.96% | -65.8% |
| Q3 2022 | $23,805,000 | +1.2% | 966,108 | -0.5% | 5.73% | +1.6% |
| Q2 2022 | $23,533,000 | -9.6% | 971,233 | -3.8% | 5.64% | -10.3% |
| Q1 2022 | $26,028,000 | +4.8% | 1,010,000 | +26.2% | 6.29% | +14.0% |
| Q4 2021 | $24,832,000 | +63.8% | 800,000 | +28.0% | 5.52% | +56.3% |
| Q3 2021 | $15,156,000 | -4.2% | 625,000 | -42.4% | 3.53% | +6.3% |
| Q2 2021 | $15,820,000 | +6.7% | 1,084,300 | +82.6% | 3.32% | +8.3% |
| Q1 2021 | $14,825,000 | – | 593,712 | – | 3.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |